News
PTN
--
0.00%
--
Global Melanocyte Stimulating Hormone Receptor Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Melanocyte Stimulating Hormone Receptor market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 2d ago
Female Sexual Dysfunction Treatment Market Size, Share 2021 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2021-2025
Apr 07, 2021 (The Expresswire) -- Global "Female Sexual Dysfunction Treatment Market" 2021 present key analysis on the market status of the Female Sexual...
The Express Wire · 04/07 05:58
COVID-19 Pandemic Effect and Impact Analysis on Melanocyte Stimulating Hormone Receptor Market by 2027
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Melanocyte Stimulating Hormone Receptor market – global...
Market Insight Reports · 04/06 20:08
Palatin Technologies Stock Appears To Be Significantly Overvalued
GuruFocus News · 04/05 07:12
Melanocyte Stimulating Hormone Receptor Market to Witness a Pronounce Growth During 2027: Ameco Research
Comserve · 03/23 09:49
Female Hypoactive Sexual Desire Disorder Therapeutics Market Growth, Size, Analysis 2021, By Industry Share, Business Strategies, Emerging Demands, Growth Rate, Recent Trends, Opportunity, and Forecast to 2025
Mar 16, 2021 (The Expresswire) -- Global “Female Hypoactive Sexual Desire Disorder Therapeutics Market” report is extensive significant analyses of the...
The Express Wire · 03/16 06:22
8-K: PALATIN TECHNOLOGIES INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/12 23:10
New Strong Sell Stocks for March 11th
Zacks.com · 03/11 13:17
Melanocyte Stimulating Hormone Receptor Market Size 2021: Analysis By Top Impacting Factors, Emerging Trends, Industry Share, Key Manufactures, Applications and Forecasts Up To 2027
Mar 10, 2021 (The Expresswire) -- “Global Melanocyte Stimulating Hormone Receptor Market" Analysis 2021-2027: The global Melanocyte Stimulating Hormone...
The Express Wire · 03/10 07:02
Cathie Wood's Ark Innovation fund is set for a big rebound Tuesday as Tesla, other tech darlings pop
Wood has been hammered lately amid a big market rotation out of high-flying tech and into cyclical value stocks in the face of higher rates.
CNBC.com · 03/09 13:22
Cathie Wood says the underlying bull market is strengthening, will benefit Ark's strategy over time
Ark Invest founder and CEO Cathie Wood spoke on CNBC's "Closing Bell" on Monday.
CNBC.com · 03/08 20:39
Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual Conference
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D.,...
PR Newswire · 03/05 12:30
Melanocortin Receptor 4 Market Development, Market Trends, Key Driven Factors, Segmentation and Forecast 2020-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 01:39:22 / Comserve Inc. / -- Melanocortin Receptor 4 market is segmented by Type, and by Application. Players, stakeholders,...
Comserve · 02/22 06:40
Palatin Technologies (PTN) Received its Third Buy in a Row
SmarterAnalyst · 02/18 11:46
H.C. Wainwright Maintains a Buy Rating on Palatin Technologies (PTN)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Palatin Technologies (PTN) today and set a price target of $2.00. The company's shares
SmarterAnalyst · 02/18 11:18
Palatin Technologies (PTN) Receives a Buy from Canaccord Genuity
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Palatin Technologies (PTN), with a price target of $3.00.
SmarterAnalyst · 02/18 11:07
Melanocortin Receptor 4 Market 2021: COVID-19 Impact, Growing Rapidly with Modern Trends, Development, Size, Share, Revenue, Demand and Forecast to 2027
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Melanocortin Receptor 4...
The Express Wire · 02/18 05:22
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue Estimates
Zacks.com · 02/18 01:37
DJ Palatin Technologies' CEO Carl Spana on Q2 2021 Results -- Earnings Call Transcript >PTN
Dow Jones · 02/17 21:29
EH, PTN, ONTX and SHIP among midday movers
Gainers: CLPS (CLPS) +275%.Comstock Mining (LODE) +176%.TDH Holdings (PETZ) +134%.Dogness (DOGZ) +54%.Onconova Therapeutics (ONTX) +50%.EHang (EH) +42%.Processa Pharmaceuticals (PCSA) +34%.ZW Data Action Technologies (CNET) +33%.Ebang International (EBON) ...
Seekingalpha · 02/17 17:40
Webull provides a variety of real-time PTN stock news. You can receive the latest news about PALATIN TECH through multiple platforms. This information may help you make smarter investment decisions.
About PTN
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.